Nilotinib tedavisi sırasında iki kez iskemik serebrovasküler atak geçiren bir kronik miyeloid lösemi olgusu

Letter to Editor

Year 2017, Volume: 42 Issue: 3, 602 - 603, 30.09.2017

https://doi.org/10.17826/cutf.324597

A chronic myeloid leukemia case with two ischemic cerebrovascular attacks during nilotinib therapy

1. Jager NG, Stuurman FE, Baars JW, Opdam FL. Cerebrovascular events during nilotinib treatment. Neth J Med. 2014;72:113-4.
2. Larson RA, Kim DW, Joatar S. ENESTnd 5-year update: Long term outcomes pf patients with chronic myeloid leukemia in chronic phase (CM-CP) treated with frontline nilotinib (NIL) versus imatinib (IM): . J Clin Oncol. 2014;32:7073.
3. Jabbour E, Kantarjian H, Chronic myeloid leukemia: 2016 update on diagnosis, therapy, and monitoring. Am J Hematol. 2016;91:252-65.
4. Tefferi A, Letendre L. Nilotinib treatment-associated peripheral artery disease and sudden death: yet another reason to stick to imatinib as front-line therapy for chronic myelogenous leukemia. Am J Hematol. 2011;86:610-1.
5. Aichberger KJ, Herndlhofer S, Schernthaner GH, Schillinger M, Mitterbauer-Hohendanner G et al. Progressive peripheral arterial occlusive disease and other vascular events during nilotinib therapy in CML. Am J Hematol. 2011;86:533-9.
6. Quintás-Cardama A, Kantarjian H, Cortes J. Nilotinib-associated vascular events. Clin Lymphoma Myeloma Leuk. 2012;12:337-40.

Year 2017, Volume: 42 Issue: 3, 602 - 603, 30.09.2017

https://doi.org/10.17826/cutf.324597

Nilotinib tedavisi sırasında iki kez iskemik serebrovasküler atak geçiren bir kronik miyeloid lösemi olgusu

1. Jager NG, Stuurman FE, Baars JW, Opdam FL. Cerebrovascular events during nilotinib treatment. Neth J Med. 2014;72:113-4.
2. Larson RA, Kim DW, Joatar S. ENESTnd 5-year update: Long term outcomes pf patients with chronic myeloid leukemia in chronic phase (CM-CP) treated with frontline nilotinib (NIL) versus imatinib (IM): . J Clin Oncol. 2014;32:7073.
3. Jabbour E, Kantarjian H, Chronic myeloid leukemia: 2016 update on diagnosis, therapy, and monitoring. Am J Hematol. 2016;91:252-65.
4. Tefferi A, Letendre L. Nilotinib treatment-associated peripheral artery disease and sudden death: yet another reason to stick to imatinib as front-line therapy for chronic myelogenous leukemia. Am J Hematol. 2011;86:610-1.
5. Aichberger KJ, Herndlhofer S, Schernthaner GH, Schillinger M, Mitterbauer-Hohendanner G et al. Progressive peripheral arterial occlusive disease and other vascular events during nilotinib therapy in CML. Am J Hematol. 2011;86:533-9.
6. Quintás-Cardama A, Kantarjian H, Cortes J. Nilotinib-associated vascular events. Clin Lymphoma Myeloma Leuk. 2012;12:337-40.

There are 6 citations in total.

MLA	İlhan, Gül. “Nilotinib Tedavisi sırasında Iki Kez Iskemik serebrovasküler Atak geçiren Bir Kronik Miyeloid lösemi Olgusu”. Cukurova Medical Journal, vol. 42, no. 3, 2017, pp. 602-3, doi:10.17826/cutf.324597.